STAT+: GSK picks up pulmonary hypertension drug with 35Pharma acquisition
Stat News • 2/25/2026
Summary
GSK is acquiring the Canadian biotech company 35Pharma. This acquisition is aimed at enhancing GSK's portfolio of medicines for lung diseases, specifically targeting pulmonary hypertension.
Advertisement
Lindy Score Breakdown (V4.2)
3h
Age
1
Sources
from cluster
2
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier97% (0.5^2/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more
Stat News • Today
STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study
Stat News • 1 day ago
STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval
Stat News • 1 day ago
STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends
Stat News • Today
STAT+: Novo reports ‘triple G’ obesity drug study results
Stat News • Today
STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments
Stat News • Today
STAT+: Digital twins, the holy grail of preventative health, are still only a ‘Frankensteinian proof of principle’
Stat News • 1 day ago
STAT+: New treatment approach could give IBD patients hope, and be a bonanza for drugmakers
Stat News • 1 day ago
STAT+: People with intellectual and development disabilities have higher rates of anxiety, depression
Stat News • 1 day ago